Difference between revisions of "Team:Sheffield/episode9"

Line 274: Line 274:
 
<h2>Introducing Our Device to the Market</h2>
 
<h2>Introducing Our Device to the Market</h2>
  
−
<p>Here we discuss further work that future iGEM teams could carry out if they wish to expand on our work, specifically how the device could be introduced to the market. </p>
+
<h2>Introducing our device to the market</h2>
  
−
<p>Both misusing antibiotics and producing a device incur costs. The costs of the mass production of the device should be modelled to see if it is less than the costs of misusing antibiotics. If so, it provides a case for investing in the device. To model this, data on the cost of materials is needs to be collected.</p>
+
<p>Misusing antibiotics and manufacturing a device incur costs. The costs of mass producing a device should be less than the costs involved in misusing antibiotics, for the device to have commercial viability in the real world. This could be modelled by taking into account the cost of materials and distribution of a device, and comparing this to the effect antibiotic resistance and misprescription has on a system such as the NHS <!--glossary tag!-->.</p>
  
−
<p>If devices used in real world applications contain genetically modified live bacteria, they would require approval from regulatory authorities. NICE (National Institute for Health and Care Excellence), and ISO (International Organization for Standardization) are two good examples. Design decisions should be made accordingly.</p>
+
<p>If our device were to become a widespread diagnostic tool, it would require approval from regulatory authorities such as National Institute for Health and Care Excellence (NICE), the Medicines and Healthcare products Regulatory Agency (MHRA) and the International Organisation for Standardization (ISO). Further, we would need to wait for rulings from UK and EU government commissions concerning whether GM<!--glossary tag!--> live bacteria could be safely distributed within a healthcare setting.</p>
  
−
<p>In addition to safety, public and private healthcare providers, such as the NHS(National Health Service) and Bupa should be consulted to understand their demand for our device. Business plans should be prepared when meeting with them. This would allow us to forecast how commonly used the device would be.</p>
+
<p>Public and private healthcare providers such as the National Health Service (NHS) and British United Provident Association (Bupa) should be consulted as these would be the end-users. We could further improve the device by conducting widespread trials in partnership with our end-users.</p>
−
 
+
−
<p>Lastly, in order to understand the needs of stakeholders, a greater number of each stakeholder should be consulted to get more representative opinions.</p>
+
  
 
</div>
 
</div>

Revision as of 19:45, 19 October 2016

A template page

THE FUTURE

Introducing Our Device to the Market

Introducing our device to the market

Misusing antibiotics and manufacturing a device incur costs. The costs of mass producing a device should be less than the costs involved in misusing antibiotics, for the device to have commercial viability in the real world. This could be modelled by taking into account the cost of materials and distribution of a device, and comparing this to the effect antibiotic resistance and misprescription has on a system such as the NHS .

If our device were to become a widespread diagnostic tool, it would require approval from regulatory authorities such as National Institute for Health and Care Excellence (NICE), the Medicines and Healthcare products Regulatory Agency (MHRA) and the International Organisation for Standardization (ISO). Further, we would need to wait for rulings from UK and EU government commissions concerning whether GM live bacteria could be safely distributed within a healthcare setting.

Public and private healthcare providers such as the National Health Service (NHS) and British United Provident Association (Bupa) should be consulted as these would be the end-users. We could further improve the device by conducting widespread trials in partnership with our end-users.